These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 22446132)
1. Use of concomitant glucose-lowering therapies and associated treatment results observed in clinical trials of twice-daily exenatide. Pencek R; Brunell SC; Li Y; Hoogwerf BJ; Malone J Endocr Pract; 2012; 18(2):227-37. PubMed ID: 22446132 [TBL] [Abstract][Full Text] [Related]
2. Exenatide once weekly for the treatment of type 2 diabetes mellitus: clinical results in subgroups of patients using different concomitant medications. Pencek R; Brunell SC; Li Y; Hoogwerf BJ; Malone J Postgrad Med; 2012 Jul; 124(4):33-40. PubMed ID: 22913892 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes. Wysham CH; Rosenstock J; Vetter ML; Dong F; Öhman P; Iqbal N Diabetes Obes Metab; 2018 Jan; 20(1):165-172. PubMed ID: 28685973 [TBL] [Abstract][Full Text] [Related]
4. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Barnett AH; Burger J; Johns D; Brodows R; Kendall DM; Roberts A; Trautmann ME Clin Ther; 2007 Nov; 29(11):2333-48. PubMed ID: 18158075 [TBL] [Abstract][Full Text] [Related]
5. Exenatide twice daily: analysis of effectiveness and safety data stratified by age, sex, race, duration of diabetes, and body mass index. Pencek R; Blickensderfer A; Li Y; Brunell SC; Anderson PW Postgrad Med; 2012 Jul; 124(4):21-32. PubMed ID: 22913891 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Moretto TJ; Milton DR; Ridge TD; Macconell LA; Okerson T; Wolka AM; Brodows RG Clin Ther; 2008 Aug; 30(8):1448-60. PubMed ID: 18803987 [TBL] [Abstract][Full Text] [Related]
7. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Heine RJ; Van Gaal LF; Johns D; Mihm MJ; Widel MH; Brodows RG; Ann Intern Med; 2005 Oct; 143(8):559-69. PubMed ID: 16230722 [TBL] [Abstract][Full Text] [Related]
8. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Buse JB; Bergenstal RM; Glass LC; Heilmann CR; Lewis MS; Kwan AY; Hoogwerf BJ; Rosenstock J Ann Intern Med; 2011 Jan; 154(2):103-12. PubMed ID: 21138825 [TBL] [Abstract][Full Text] [Related]
9. Exenatide twice daily versus insulin glargine for the treatment of type 2 diabetes in Poland - subgroup data from a randomised multinational trial GWAA. Matyjaszek-Matuszek B; Lenart-Lipińska M; Rogalska D; Nowakowski A; Endokrynol Pol; 2013; 64(5):375-82. PubMed ID: 24186595 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea. Bergenstal R; Lewin A; Bailey T; Chang D; Gylvin T; Roberts V; Curr Med Res Opin; 2009 Jan; 25(1):65-75. PubMed ID: 19210140 [TBL] [Abstract][Full Text] [Related]
11. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Zinman B; Hoogwerf BJ; Durán García S; Milton DR; Giaconia JM; Kim DD; Trautmann ME; Brodows RG Ann Intern Med; 2007 Apr; 146(7):477-85. PubMed ID: 17404349 [TBL] [Abstract][Full Text] [Related]
12. Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years. Norwood P; Liutkus JF; Haber H; Pintilei E; Boardman MK; Trautmann ME Clin Ther; 2012 Oct; 34(10):2082-90. PubMed ID: 23031623 [TBL] [Abstract][Full Text] [Related]
13. [Twice-daily and weekly exenatide: clinical profile of two pioneer formulations in incretin therapy]. Lecube A; Bueno M; Suárez X Med Clin (Barc); 2014 Sep; 143 Suppl 2():23-7. PubMed ID: 25437462 [TBL] [Abstract][Full Text] [Related]
14. Long-term effects of adding exenatide to a regimen of metformin and/or sulfonylurea in type 2 diabetes: an uncontrolled, open-label trial in Hungary. Iványi T; Fövényi J; Faludi P; Han J; Macconell L; Wille S; Kiljanski J Clin Ther; 2012 Jun; 34(6):1301-13. PubMed ID: 22608106 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis. Pinelli NR; Hurren KM Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278 [TBL] [Abstract][Full Text] [Related]
16. Five-year efficacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trial. Wysham CH; MacConell LA; Maggs DG; Zhou M; Griffin PS; Trautmann ME Mayo Clin Proc; 2015 Mar; 90(3):356-65. PubMed ID: 25744115 [TBL] [Abstract][Full Text] [Related]
17. Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. Simó R; Guerci B; Schernthaner G; Gallwitz B; Rosas-Guzmàn J; Dotta F; Festa A; Zhou M; Kiljański J Cardiovasc Diabetol; 2015 Sep; 14():116. PubMed ID: 26338040 [TBL] [Abstract][Full Text] [Related]
18. Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes. Diamant M; Nauck MA; Shaginian R; Malone JK; Cleall S; Reaney M; de Vries D; Hoogwerf BJ; MacConell L; Wolffenbuttel BH; Diabetes Care; 2014 Oct; 37(10):2763-73. PubMed ID: 25011946 [TBL] [Abstract][Full Text] [Related]
19. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. Blevins T; Pullman J; Malloy J; Yan P; Taylor K; Schulteis C; Trautmann M; Porter L J Clin Endocrinol Metab; 2011 May; 96(5):1301-10. PubMed ID: 21307137 [TBL] [Abstract][Full Text] [Related]
20. Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the DURATION trials. Grimm M; Han J; Weaver C; Griffin P; Schulteis CT; Dong H; Malloy J Postgrad Med; 2013 May; 125(3):47-57. PubMed ID: 23748506 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]